Literature DB >> 28578437

Clinical value of combining transvaginal contrast-enhanced ultrasonography with serum human epididymisprotein-4 and the resistance index for early-stage epithelial ovarian cancer.

Wu Meng1, Wang Ying, Zheng Qichao, Li Ping, Tang Jie.   

Abstract

OBJECTIVES: To increase accuracy of the detection and differential diagnosis of the early epithelial ovarian cancer (EOC) with transvaginal contrast-enhanced ultrasonography (TVCEUS) combining serum human epididymisprotein 4 (HE4), and resistance index (RI). 
Methods: This retrospectively case-control study of 230 patients with ovarian tumors were reviewed at the Department of Gynecology and Obstetrics, Zhongnan Hospital, Wuhan University, Wuhan, China between June 2008 and September 2015. Before the operation of 110 cases with EOC (Group A) and 120 cases of patients with benign ovarian tumor (Group B), we observe and calculate both Groups' tumor vascular contrast-enhanced ultrasonography morphology scores (U), time-intensity curve (TIC) of contrast-enhanced ultrasonography, HE4, and RI. Results were compared with the histopathological analysis results. 
Results: The ultrasonography morphology scores, peak intensity (PI) enhancement rate (ER) with the parameters of the TIC and HE4 are higher in Group A compared with patients in Group B and the RI was lower than Group B. The detection rates for all indexes in the benign and malignant groups and their comparisons to the histopathological results were determined. The detection rate differences for HE4 (p=0.001), RI (p=0.001), U (p=0.001), PI (p=0.001), and ER (p=0.001) were all statistically significant (p less than 0.05).  
Conclusion: The high clinical value through combined TVCEUS, HE4, and RI detection can increase the sensitivity of the diagnosis and differential diagnosis of the early EOC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28578437      PMCID: PMC5541181          DOI: 10.15537/smj.2017.6.19790

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  24 in total

1.  Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma.

Authors:  Xiaohong Chang; Xue Ye; Li Dong; Hongyan Cheng; Yexia Cheng; Lirong Zhu; Qinping Liao; Yang Zhao; Li Tian; Tianyun Fu; Jun Chen; Heng Cui
Journal:  Int J Gynecol Cancer       Date:  2011-07       Impact factor: 3.437

2.  The use of contrasted transvaginal sonography in the diagnosis of gynecologic diseases: a preliminary study.

Authors:  Antonia Carla Testa; Gabriella Ferrandina; Erika Fruscella; Caroline Van Holsbeke; Enrico Ferrazzi; Francesco P G Leone; Domenico Arduini; Caterina Exacoustos; Daniela Bokor; Giovanni Scambia; Dirk Timmerman
Journal:  J Ultrasound Med       Date:  2005-09       Impact factor: 2.153

3.  Doppler ultrasound measurement of resistance index in the diagnosis of prostate cancer.

Authors:  Wei Huang; Son Cen; Xin-Li Kang; Wei Fu Wang; Yang Wang; Xiang Chen
Journal:  Tumori       Date:  2015-05-18       Impact factor: 2.098

4.  HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm.

Authors:  Giuseppina Ruggeri; Elisabetta Bandiera; Laura Zanotti; Silvana Belloli; Antonella Ravaggi; Chiara Romani; Eliana Bignotti; Renata A Tassi; Germana Tognon; Claudio Galli; Luigi Caimi; Sergio Pecorelli
Journal:  Clin Chim Acta       Date:  2011-04-30       Impact factor: 3.786

5.  Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer.

Authors:  Seungho Lee; Seowon Choi; Yookyung Lee; Donghae Chung; Suntaek Hong; Nohhyun Park
Journal:  J Obstet Gynaecol Res       Date:  2016-11-12       Impact factor: 1.730

6.  Contrast-enhanced transvaginal sonography of benign versus malignant ovarian masses: preliminary findings.

Authors:  Arthur C Fleischer; Andrej Lyshchik; Howard W Jones; Marta Crispens; Mary Loveless; Rochelle F Andreotti; Phillip K Williams; David A Fishman
Journal:  J Ultrasound Med       Date:  2008-07       Impact factor: 2.153

7.  Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.

Authors:  Mona Aarenstrup Karlsen; Noreen Sandhu; Claus Høgdall; Ib Jarle Christensen; Lotte Nedergaard; Lene Lundvall; Svend A Engelholm; Anette T Pedersen; Dorthe Hartwell; Magnus Lydolph; Inga Alice Laursen; Estrid V S Høgdall
Journal:  Gynecol Oncol       Date:  2012-07-24       Impact factor: 5.482

8.  Evaluation of the effects of acupuncture on blood flow in humans with ultrasound color Doppler imaging.

Authors:  Shin Takayama; Masashi Watanabe; Hiroko Kusuyama; Satoru Nagase; Takashi Seki; Toru Nakazawa; Nobuo Yaegashi
Journal:  Evid Based Complement Alternat Med       Date:  2012-06-21       Impact factor: 2.629

9.  Contrast-enhanced ultrasonography in differential diagnosis of benign and malignant ovarian tumors.

Authors:  Jing-Jing Qiao; Jing Yu; Zhe Yu; Na Li; Chen Song; Man Li
Journal:  PLoS One       Date:  2015-03-12       Impact factor: 3.240

10.  Contrast-enhanced ultrasound in ovarian tumors - diagnostic parameters: method presentation and initial experience.

Authors:  Anita-Roxana Maxim; Radu Badea; Atilla Tamas; Alexandru Traila
Journal:  Clujul Med       Date:  2013-02-04
View more
  2 in total

1.  Value of preoperative staging of endometrial carcinoma with contrast-enhanced ultrasonography: A PRISMA compliant meta-analysis.

Authors:  Xiaozhen Tong; Xiaofen Wu; Qiaohong Zhang
Journal:  Medicine (Baltimore)       Date:  2021-04-09       Impact factor: 1.817

2.  Diagnostic Value of Two-Dimensional Transvaginal Ultrasound Combined with Contrast-Enhanced Ultrasound in Ovarian Cancer.

Authors:  Rong Hu; Gulina Shahai; Hui Liu; Yuling Feng; Hong Xiang
Journal:  Front Surg       Date:  2022-05-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.